356 related articles for article (PubMed ID: 20473488)
1. Sclerostin: current knowledge and future perspectives.
Moester MJ; Papapoulos SE; Löwik CW; van Bezooijen RL
Calcif Tissue Int; 2010 Aug; 87(2):99-107. PubMed ID: 20473488
[TBL] [Abstract][Full Text] [Related]
2. Targeted deletion of Sost distal enhancer increases bone formation and bone mass.
Collette NM; Genetos DC; Economides AN; Xie L; Shahnazari M; Yao W; Lane NE; Harland RM; Loots GG
Proc Natl Acad Sci U S A; 2012 Aug; 109(35):14092-7. PubMed ID: 22886088
[TBL] [Abstract][Full Text] [Related]
3. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation.
van Bezooijen RL; ten Dijke P; Papapoulos SE; Löwik CW
Cytokine Growth Factor Rev; 2005 Jun; 16(3):319-27. PubMed ID: 15869900
[TBL] [Abstract][Full Text] [Related]
4. Targeting sclerostin as potential treatment of osteoporosis.
Papapoulos SE
Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i119-22. PubMed ID: 21339215
[TBL] [Abstract][Full Text] [Related]
5. Activating the unfolded protein response in osteocytes causes hyperostosis consistent with craniodiaphyseal dysplasia.
Chan WCW; Tsang KY; Cheng YW; Ng VCW; Chik H; Tan ZJ; Boot-Handford R; Boyde A; Cheung KMC; Cheah KSE; Chan D
Hum Mol Genet; 2017 Dec; 26(23):4572-4587. PubMed ID: 28973168
[TBL] [Abstract][Full Text] [Related]
6. Genetics of Sost/SOST in sclerosteosis and van Buchem disease animal models.
Sebastian A; Loots GG
Metabolism; 2018 Mar; 80():38-47. PubMed ID: 29080811
[TBL] [Abstract][Full Text] [Related]
7. Bone morphogenetic proteins and their antagonists: the sclerostin paradigm.
van Bezooijen RL; Papapoulos SE; Löwik CW
J Endocrinol Invest; 2005; 28(8 Suppl):15-7. PubMed ID: 16323824
[TBL] [Abstract][Full Text] [Related]
8. Sclerostin deficiency in humans.
van Lierop AH; Appelman-Dijkstra NM; Papapoulos SE
Bone; 2017 Mar; 96():51-62. PubMed ID: 27742500
[TBL] [Abstract][Full Text] [Related]
9. Sclerostin: recent advances and clinical implications.
Honasoge M; Rao AD; Rao SD
Curr Opin Endocrinol Diabetes Obes; 2014 Dec; 21(6):437-46. PubMed ID: 25333305
[TBL] [Abstract][Full Text] [Related]
10. Modulation of sclerostin expression by mechanical loading and bone morphogenetic proteins in osteogenic cells.
Papanicolaou SE; Phipps RJ; Fyhrie DP; Genetos DC
Biorheology; 2009; 46(5):389-99. PubMed ID: 19940355
[TBL] [Abstract][Full Text] [Related]
11. Identification of the disease-causing gene in sclerosteosis--discovery of a novel bone anabolic target?
Balemans W; Van Hul W
J Musculoskelet Neuronal Interact; 2004 Jun; 4(2):139-42. PubMed ID: 15615113
[TBL] [Abstract][Full Text] [Related]
12. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling.
ten Dijke P; Krause C; de Gorter DJ; Löwik CW; van Bezooijen RL
J Bone Joint Surg Am; 2008 Feb; 90 Suppl 1():31-5. PubMed ID: 18292354
[TBL] [Abstract][Full Text] [Related]
13. Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition.
Witcher PC; Miner SE; Horan DJ; Bullock WA; Lim KE; Kang KS; Adaniya AL; Ross RD; Loots GG; Robling AG
JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875318
[TBL] [Abstract][Full Text] [Related]
14. The sclerostin story: from human genetics to the development of novel anabolic treatment for osteoporosis.
Yavropoulou MP; Xygonakis C; Lolou M; Karadimou F; Yovos JG
Hormones (Athens); 2014; 13(4):323-37. PubMed ID: 25555179
[TBL] [Abstract][Full Text] [Related]
15. Sclerostin and skeletal health.
Sharifi M; Ereifej L; Lewiecki EM
Rev Endocr Metab Disord; 2015 Jun; 16(2):149-56. PubMed ID: 25669441
[TBL] [Abstract][Full Text] [Related]
16. A Novel Domain-Specific Mutation in a Sclerosteosis Patient Suggests a Role of LRP4 as an Anchor for Sclerostin in Human Bone.
Fijalkowski I; Geets E; Steenackers E; Van Hoof V; Ramos FJ; Mortier G; Fortuna AM; Van Hul W; Boudin E
J Bone Miner Res; 2016 Apr; 31(4):874-81. PubMed ID: 26751728
[TBL] [Abstract][Full Text] [Related]
17. Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function.
Leupin O; Piters E; Halleux C; Hu S; Kramer I; Morvan F; Bouwmeester T; Schirle M; Bueno-Lozano M; Fuentes FJ; Itin PH; Boudin E; de Freitas F; Jennes K; Brannetti B; Charara N; Ebersbach H; Geisse S; Lu CX; Bauer A; Van Hul W; Kneissel M
J Biol Chem; 2011 Jun; 286(22):19489-500. PubMed ID: 21471202
[TBL] [Abstract][Full Text] [Related]
18. Sclerostin: Intracellular mechanisms of action and its role in the pathogenesis of skeletal and vascular disorders.
Pietrzyk B; Smertka M; Chudek J
Adv Clin Exp Med; 2017 Nov; 26(8):1283-1291. PubMed ID: 29264888
[TBL] [Abstract][Full Text] [Related]
19. From disease to treatment: from rare skeletal disorders to treatments for osteoporosis.
Appelman-Dijkstra NM; Papapoulos SE
Endocrine; 2016 Jun; 52(3):414-26. PubMed ID: 26892377
[TBL] [Abstract][Full Text] [Related]
20. An Akt-dependent increase in canonical Wnt signaling and a decrease in sclerostin protein levels are involved in strontium ranelate-induced osteogenic effects in human osteoblasts.
Rybchyn MS; Slater M; Conigrave AD; Mason RS
J Biol Chem; 2011 Jul; 286(27):23771-9. PubMed ID: 21566129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
